Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT03172455 |
|
Expanded Access Status :
Available
First Posted : June 1, 2017
Last Update Posted : November 14, 2018
|
- Study Details
- Tabular View
- Disclaimer
- How to Read a Study Record
An Early Access Program for patients with steroid refractory acute GvHD after hematopoietic stem cell transplantation.
This Program is available for female and male who are recipients of allogenic HSCT and who have been newly diagnosed with acute GvHD.
| Condition or disease | Intervention/treatment |
|---|---|
| Acute-graft-versus-host Disease Steroid Refractory Acute Graft Versus Host Disease Graft-versus-host-disease Graft Vs Host Disease Alpha 1-Antitrypsin Deficiency Alpha-1 Proteinase Inhibitor Alpha-1 Protease Inhibitor Deficiency Acute Graft-Versus-Host Reaction Following Bone Marrow Transplant | Drug: Glassia |
GLASSIA (human alpha-1 proteinase inhibitor (A1PI), also known as human alpha-1 antitrypsin, Kamada-AAT or Kamada-API) is a, liquid, ready-to-use preparation of human A1PI. Alpha-1 proteinase inhibitor belongs to the family of serine proteinase inhibitors and is primarily produced in the liver and secreted into the circulation. In addition to its anti-proteinase activity, A1PI showed to have anti-inflammatory, anti-apoptotic and immunomodulatory properties (1-4).
GLASSIA is an injection solution prepared from human plasma collected from healthy volunteer blood donors in accordance with Food and Drug Administration (FDA) and European Medicines Agency (EMA) regulations. GLASSIA was approved in the United States (US) in July 2010 and is indicated for chronic augmentation and maintenance therapy in adults with clinically evident emphysema due to severe hereditary deficiency of Alpha1-PI (alpha1-antitrypsin deficiency).
| Study Type : | Expanded Access |
| Official Title: | Early Access Program Using Alpha 1 Antitrypsin Infusion for Patients With Steroid Refractory Acute GvHD After Hematopoietic Stem Cell Transplantation (HSCT) |
- Drug: Glassia
Application 90 mg/kg loading dose day 1, 30 mg/kg every other day (day 3 - day 15)Other Name: Alpha 1 antitrypsin
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | Child, Adult, Older Adult |
| Sexes Eligible for Study: | All |
Inclusion Criteria:
- This program is available for patients who suffer from steroid refractory acute GvHD after HSCT, or for whom, in the opinion of their treating physician, other treatment options or clinical trials in this indication are unsuitable.
- The disease indication for which the participant required HSCT must be in remission
- Acute graft-versus-host disease (aGvHD), including lower GI involvement (modified
- International Bone Marrow Transplant Registry (IBMTR) Severity Stage 1 to 4 [>500 mL diarrhea/day]), with or without other organ system involvement.
- For women of childbearing potential, had a negative serum or urine pregnancy test within 14 days prior to enrolment.
Exclusion Criteria:
- Participant with manifestations of chronic GvHD
- Participant with acute/chronic GvHD overlap syndrome
- Participant whose GvHD developed after donor lymphocyte infusion
- Participant with severe sepsis involving at least 1 organ failure
- Participant who is seropositive or positive in the nucleic acid test for human immunodeficiency virus (HIV)
- Participant with active hepatitis B or C
- If female, participant is pregnant or lactating at the time of enrollment, or has plans to become pregnant during the program
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03172455
| Contact: Michel van Harten, MD | +31 885253888 | michel.vanharten@mytomorrows.com | |
| Contact: Karlijn Doorn, PhD | +31 885253888 | karlijn.doorn@mytomorrows.com |
Publications:
| Responsible Party: | Impatients N.V. trading as myTomorrows |
| ClinicalTrials.gov Identifier: | NCT03172455 History of Changes |
| Other Study ID Numbers: |
2017-AATGLAKAM-EU |
| First Posted: | June 1, 2017 Key Record Dates |
| Last Update Posted: | November 14, 2018 |
| Last Verified: | November 2018 |
|
Alpha 1-Antitrypsin Deficiency Graft vs Host Disease Immune System Diseases Liver Diseases Digestive System Diseases Lung Diseases Respiratory Tract Diseases Genetic Diseases, Inborn Subcutaneous Emphysema |
Emphysema Pathologic Processes Alpha 1-Antitrypsin Protein C Inhibitor Trypsin Inhibitors Serine Proteinase Inhibitors Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action |